Seattle Genetics bags new milestones under Genentech ADC collaboration
This article was originally published in Scrip
Seattle Genetics has earned undisclosed milestone payments under its antibody-drug conjugate (ADC) collaboration with Roche's Genentech unit after Genentech advanced two ADCs developed with Seattle Genetics' technology into Phase II development.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.